SCHEMBL6504994

SCHEMBL6504994

CNC(=O)c1ccc(-c2cccc(-n3cc(NC(N)=O)c(C(N)=O)n3)c2)cc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IRAK4 Q9NWZ3 4/20 0.48
ITK Q08881 1/20 0.44
KDM4E B2RXH2 5/20 0.43
LMNA P02545 4/20 0.43
MAPT P10636 4/20 0.43
SCN9A Q15858 1/20 0.41
ALDH1A1 P00352 4/20 0.41
PIK3CG P48736 1/20 0.41
IKBKB O14920 1/20 0.41
HPGD P15428 1/20 0.40
MKNK1 Q9BUB5 1/20 0.39
MKNK2 Q9HBH9 1/20 0.39
SMN1; SMN2 Q16637 2/20 0.39
PDCD1 Q15116 1/20 0.39
CD274 Q9NZQ7 1/20 0.39
ATM Q13315 1/20 0.39
CHEK1 O14757 1/20 0.38
MAP4K4 O95819 1/20 0.38
NPC1 O15118 1/20 0.38
TP53 P04637 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6469989 0.93 IRAK4 (0.56) IRAK4ITKKDM4ELMNAMAPT
SCHEMBL6504845 0.89 ITK (0.46) IRAK4ITKKDM4ELMNAMAPT
SCHEMBL6505259 0.89 KDM4E (0.44) IRAK4ITKKDM4ELMNAMAPT
SCHEMBL6500705 0.88 MEN1 (0.44) IRAK4ITKKDM4ELMNAMAPT
SCHEMBL6468716 0.87 BACE1 (0.44) IRAK4ITKKDM4ELMNAMAPT
SCHEMBL6507525 0.86 KIF11 (0.45) IRAK4ITKKDM4ELMNAMAPT
SCHEMBL6509124 0.86 RAB9A (0.49) IRAK4ITKKDM4ELMNAMAPT
SCHEMBL6468696 0.86 TP53 (0.43) IRAK4ITKKDM4ELMNAMAPT
SCHEMBL6501255 0.86 ITK (0.45) IRAK4ITKKDM4ELMNAMAPT
SCHEMBL6499548 0.86 ITK (0.45) IRAK4ITKKDM4ELMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation PHARMACIA AND UPJOHN COMPANY LLC 2005-09-08 US disclosed
US-20050080113-A1 Medicinal compositions TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2005-04-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050080113-A1 Medicinal compositions TNF, TRAF6, MMP8 IRAK4 382/4885ITK 2987/4885KDM4E 4034/4885
US-20050197338-A1 Substituted pyrazole urea compounds for the treatment of inflammation IL4, ARG2, CASP4 IRAK4 27/4885ITK 4236/4885KDM4E 2424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.